ES2151880T3 - Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones. - Google Patents

Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.

Info

Publication number
ES2151880T3
ES2151880T3 ES91920567T ES91920567T ES2151880T3 ES 2151880 T3 ES2151880 T3 ES 2151880T3 ES 91920567 T ES91920567 T ES 91920567T ES 91920567 T ES91920567 T ES 91920567T ES 2151880 T3 ES2151880 T3 ES 2151880T3
Authority
ES
Spain
Prior art keywords
viia
factors vii
factor
complex
tissue factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920567T
Other languages
English (en)
Spanish (es)
Inventor
Howard R Soule
Terence K Brunck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Pharmaceuticals LLC
Original Assignee
Corvas International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvas International Inc filed Critical Corvas International Inc
Application granted granted Critical
Publication of ES2151880T3 publication Critical patent/ES2151880T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES91920567T 1990-10-22 1991-10-17 Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones. Expired - Lifetime ES2151880T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60145490A 1990-10-22 1990-10-22
US07/759,443 US5506134A (en) 1990-10-22 1991-09-13 Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex

Publications (1)

Publication Number Publication Date
ES2151880T3 true ES2151880T3 (es) 2001-01-16

Family

ID=27083860

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920567T Expired - Lifetime ES2151880T3 (es) 1990-10-22 1991-10-17 Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.

Country Status (9)

Country Link
US (1) US5506134A (cg-RX-API-DMAC7.html)
EP (1) EP0554383B1 (cg-RX-API-DMAC7.html)
JP (1) JP2680192B2 (cg-RX-API-DMAC7.html)
AT (1) ATE195149T1 (cg-RX-API-DMAC7.html)
AU (1) AU654311B2 (cg-RX-API-DMAC7.html)
CA (1) CA2094372A1 (cg-RX-API-DMAC7.html)
DE (1) DE69132352T2 (cg-RX-API-DMAC7.html)
ES (1) ES2151880T3 (cg-RX-API-DMAC7.html)
WO (1) WO1992006711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
AU1378495A (en) * 1993-12-27 1995-07-17 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
US5683899A (en) * 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
BR9915460A (pt) * 1998-11-20 2001-07-17 Lilly Co Eli Método de tratamento de febre hemorrágica virótica
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
AU1624801A (en) 1999-11-19 2001-05-30 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE60126143T2 (de) 2000-12-06 2007-11-15 Sanofi-Aventis Deutschland Gmbh Guanidin- und amidin-verbindungen, und ihre verwendung als faktor xa-inhibitoren
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
AU2002240000A1 (en) * 2001-01-23 2002-08-06 Saint Louis University Factor ixa: factor viiia interaction and methods therefor
EP1260817A3 (en) 2001-05-08 2002-12-18 Warner-Lambert Company Method for direct measurement of coagulation factor VIIa activity in plasma
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
ES2407355T3 (es) * 2001-07-03 2013-06-12 Oklahoma Medical Research Foundation Ensayo para medir los complejos de factor VIIa-antitrombina
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
JP2005510515A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US20040126856A1 (en) * 2002-01-23 2004-07-01 Bajaj Paul S. Factor ixa: factor Vllla interaction and methods therefor
EP1476186A1 (en) * 2002-02-22 2004-11-17 Prophy Med AB Use of an inhibitor or antagonist against tissue factor
US6706068B2 (en) 2002-04-23 2004-03-16 Bret A. Ferree Artificial disc replacements with natural kinematics
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
ES2323056T3 (es) * 2002-05-01 2009-07-06 Bayer Schering Pharma Aktiengesellschaft Anticuerpos dirigidos contra factor tisular como anticoagulantes.
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
PL1641916T3 (pl) 2003-06-27 2016-08-31 Depuy Synthes Products Inc Regeneracja i naprawa tkanki nerwowej z wykorzystaniem komórek poporodowych
DE10333508A1 (de) * 2003-07-18 2005-02-17 Technische Universität Dresden Gegen Prothrombin gerichtete Erkennungsmoleküle und die Verwendung dieser
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
WO2006033669A2 (en) * 2004-04-16 2006-03-30 The Scripps Research Institute Method of modulating vascularization
ES2621847T3 (es) 2004-12-23 2017-07-05 DePuy Synthes Products, Inc. Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas
HRP20181727T1 (hr) * 2008-06-19 2019-02-08 Prothix Bv Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
HRP20171789T1 (hr) 2010-06-15 2017-12-29 Genmab A/S Konjugati humanog protutijela s lijekom protiv tkivnog faktora
CA2841185C (en) 2011-07-22 2021-05-25 Csl Behring Gmbh Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses
JP6346895B2 (ja) 2012-09-13 2018-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ミオスタチンと結合するフィブロネクチンベースの足場ドメインタンパク質
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
SG11202010993VA (en) 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
KR20240046282A (ko) 2019-04-17 2024-04-08 노보 노르디스크 에이/에스 이중 특이적 항체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
SE461315B (sv) * 1988-06-16 1990-02-05 Jan Niels Faergemann Anvaendning av en komposition innehaallande aluminiumacetotartrat och en diol foer att minska hudirritationer orsakade av urin eller avfoering, samt bloeja impregnerad med kompositionen
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides

Also Published As

Publication number Publication date
EP0554383A1 (en) 1993-08-11
AU654311B2 (en) 1994-11-03
US5506134A (en) 1996-04-09
WO1992006711A1 (en) 1992-04-30
EP0554383A4 (cg-RX-API-DMAC7.html) 1994-04-27
AU9029891A (en) 1992-05-20
EP0554383B1 (en) 2000-08-02
JP2680192B2 (ja) 1997-11-19
DE69132352D1 (de) 2000-09-07
ATE195149T1 (de) 2000-08-15
CA2094372A1 (en) 1992-04-23
JPH06502307A (ja) 1994-03-17
DE69132352T2 (de) 2001-03-15

Similar Documents

Publication Publication Date Title
ES2151880T3 (es) Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.
DE69626832D1 (de) Blutbehandlungssysteme und methoden zur gewinnung von mononuklearen zellen
DE3577650D1 (de) Vorrichtung zur dehnung von koerpergewebe.
OA09478A (fr) "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".
DE69023577D1 (de) Ultraschallsystem zur Bestimmung des Profils von Festkörpern.
DE68925226D1 (de) Monoklonale Antikörper
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE347697T1 (de) Methode zur bestimmung von proteinfragmenten in körperflüssigkeiten
FR2491334B1 (cg-RX-API-DMAC7.html)
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
BR9713450A (pt) Quimiocinas de mamìfero
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
PT86944A (pt) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben
FR2608767B1 (fr) Procede pour la detection et le dosage des anticorps anti-(sporozoaires de p. falciparum) dans le sang humain et trousses de diagnostic pour mettre en oeuvre ce procede
FI873606A7 (fi) Ihmisen glykoalbumiinin määrittämiseen käyttökelpoisia vasta-aineita.
DE69426028D1 (de) Reagenz für die enzymatische Bestimmung des Bikarbonatgehalts in Blutserum
FI844645L (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 554383

Country of ref document: ES